ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 154

Frequency of Fibromyalgia in Patients with Antiphospholipid Syndrome. a Cross-Sectional Study

Nicole Mouneu Ornelas1, Laura-Aline Martinez-Martinez2, Vijaya Rivera3, Ricardo Alberto Venegas Yañez4, Victor Alejandro Escamilla Gomez5, Gumaro Acosta Peña6, Luis H. Silveira7, Angelica Vargas Guerrero3, Luis M. Amezcua-Guerra3 and Manuel Martínez-Lavín3, 1Internal Medicine, Instituto Nacional de Cardiología - Ignacio Chávez, IGNACIO CHÁVEZ, Mexico, 2Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, TX, Mexico, 3Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 4Reumatologia, Instituto Nacional de Cardiología "Ignacio Chavez", Ciudad de México, Mexico, 5Rheumatology, Instituto Nacional de Cardiología - Ignacio Chávez, Mexico City, Mexico, 6Instituto Nacional de Cardiología, Ciudad de mexico, Mexico, 7Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Antiphospholipid syndrome and fibromyalgia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The observation of several cases with coexistent antiphospholipid syndrome (APS) and fibromyalgia led us to this investigation. The objective was to define the frequency of fibromyalgia in a group of patients with antiphospholipid syndrome.

Methods:

From March 24th to June 8th 2017 we studied all APS patients attending our outpatient rheumatology clinic. All of them fulfilled the Sapporo and/or Sydney APS classification criteria. The Institutional Ethics Committee approved the protocol. All patients underwent a history + physical examination with emphasis on musculoskeletal features. All filled-out the following questionnaires: the Revised Fibromyalgia Impact Questionnaire (FIQ-R), the 2016 revision of Wolfe’s Fibromyalgia Diagnostic Criteria, and the quality of life EuroQol 5D-5L. The Damage Index in Thrombotic Antiphospholipid Syndrome (DIAPS) was also obtained. Spearman method was used to correlate APS clinical features with fibromyalgia questionnaire scales. Chi square to compare categorical variables.

Results:

Sixty one patients with APS were included. Their mean age: 44 ± 15 years, 70% are female and 54% have primary APS. The prevalence of fibromyalgia was different when using the 1990 ACR diagnostic criteria (4.9%) compared to Wolfe’s criteria (16.4%) p<0.0001. The frequency of fibromyalgia was not different in patient with primary vs. secondary APS. In those patient who had concurrent APS and fibromyalgia according to Wolfe’s criteria (n = 10), there was a correlation between total number of thrombotic events with headache, depression, and abdominal pain (r=0.636, p=0.048), as well as with FIQ-R balance problems (r=0.754, p=0.012). Oddly, cumulative organ damage measured by DIAPS inversely correlated with FIQ-R quality of sleep (r=-0.820, p=0.004). Quality of life measured by Euro Qol is poorer in APS + fibromyalgia patients (85±16 vs 64±12, p<0.001).

Conclusion:

In this cohort of patients with APS, more individuals can be classified as having concurrent fibromyalgia when the 2016 revised Wolfe’s criteria is used. Recurrent thrombosis is associated to several fibromyalgia symptoms such as headache, depression and abdominal pain. Patients with APS and concurrent fibromyalgia have poorer quality life.


Disclosure: N. M. Ornelas, None; L. A. Martinez-Martinez, None; V. Rivera, None; R. A. Venegas Yañez, None; V. A. Escamilla Gomez, None; G. Acosta Peña, None; L. H. Silveira, None; A. Vargas Guerrero, None; L. M. Amezcua-Guerra, None; M. Martínez-Lavín, None.

To cite this abstract in AMA style:

Ornelas NM, Martinez-Martinez LA, Rivera V, Venegas Yañez RA, Escamilla Gomez VA, Acosta Peña G, Silveira LH, Vargas Guerrero A, Amezcua-Guerra LM, Martínez-Lavín M. Frequency of Fibromyalgia in Patients with Antiphospholipid Syndrome. a Cross-Sectional Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/frequency-of-fibromyalgia-in-patients-with-antiphospholipid-syndrome-a-cross-sectional-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequency-of-fibromyalgia-in-patients-with-antiphospholipid-syndrome-a-cross-sectional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology